These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients. Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242 [TBL] [Abstract][Full Text] [Related]
7. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients. Monforte V; Román A; Gavaldà J; Bravo C; Gispert P; Pahissa A; Morell F Transplant Proc; 2005 Nov; 37(9):4039-42. PubMed ID: 16386621 [TBL] [Abstract][Full Text] [Related]
8. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients. Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406 [TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen. Thomas LD; Milstone AP; Miller GG; Loyd JE; Stephen Dummer J Clin Transplant; 2009; 23(4):476-83. PubMed ID: 19453645 [TBL] [Abstract][Full Text] [Related]
10. Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation. Gerna G; Lilleri D; Callegaro A; Goglio A; Cortese S; Stroppa P; Torre G Transplantation; 2008 Jul; 86(1):163-6. PubMed ID: 18622294 [TBL] [Abstract][Full Text] [Related]
11. Oral ganciclovir shows benefit for prevention of CMV disease in liver transplant recipients. J Int Assoc Physicians AIDS Care; 1996 Jul; 2(7):43-4. PubMed ID: 11363747 [TBL] [Abstract][Full Text] [Related]
12. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Doyle AM; Warburton KM; Goral S; Blumberg E; Grossman RA; Bloom RD Transplantation; 2006 Apr; 81(8):1106-11. PubMed ID: 16641594 [TBL] [Abstract][Full Text] [Related]
13. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021 [TBL] [Abstract][Full Text] [Related]
14. Prophylaxis for cytomegalovirus in pancreas transplant recipients using intravenous ganciclovir. Kohli V; Velosa J; Sterioff S; Munn SR Transplant Proc; 1995 Dec; 27(6):2993. PubMed ID: 8539806 [No Abstract] [Full Text] [Related]
15. Ganciclovir therapy in an immunocompetent child with resistant fever and hepatosplenomegaly due to cytomegalovirus infection. Who and when to treat? Tezer H; Devrim I; Kara A; Cengiz AB; Seçmeer G Int J Infect Dis; 2008 May; 12(3):340-2. PubMed ID: 18023387 [No Abstract] [Full Text] [Related]
16. Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation. Szer J; Durrant S; Schwarer AP; Bradstock KF; Gibson J; Arthur C; To LB; Hughes T; Raunow H Intern Med J; 2004 Mar; 34(3):98-101. PubMed ID: 15030456 [TBL] [Abstract][Full Text] [Related]
17. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. Razonable RR; van Cruijsen H; Brown RA; Wilson JA; Harmsen WS; Wiesner RH; Smith TF; Paya CV J Infect Dis; 2003 Jun; 187(11):1801-8. PubMed ID: 12751039 [TBL] [Abstract][Full Text] [Related]
18. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients. Murray BM; Subramaniam S Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220 [TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus prophylaxis with IV ganciclovir in lung transplant recipients: the long and the short of it! Orens JB Chest; 1999 Nov; 116(5):1152-3. PubMed ID: 10559066 [No Abstract] [Full Text] [Related]
20. Does high-dose prophylactic acyclovir add benefit in allogeneic marrow transplant recipients receiving prophylactic or preemptive ganciclovir? de la Cámara R; Fernández-Rañada JM J Infect Dis; 1999 Aug; 180(2):571-4. PubMed ID: 10395887 [No Abstract] [Full Text] [Related] [Next] [New Search]